FHD-286 in Subjects With Metastatic Uveal Melanoma

ClinicalTrials.gov ID: NCT04879017

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT04879017. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286 in Subjects With Metastatic Uveal Melanoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).

Study identification

NCT ID: NCT04879017
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Foghorn Therapeutics Inc.; Industry
Enrollment: 76 participants

Conditions and interventions

Conditions

Metastatic Uveal Melanoma

Interventions

FHD-286 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 11, 2021 (Actual)
Primary completion: Nov 30, 2023 (Actual)
Completion: Nov 30, 2023 (Actual)
Last update posted: Apr 25, 2024

2021 – 2023

United States locations

U.S. sites: 9
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
The Angeles Clinic and Research Institute	Los Angeles	California	90025	—
University of Miami Health System, Sylvester Comprehensive Cancer Center	Miami	Florida	33136	—
Massachusetts General Hospital	Boston	Massachusetts	02114	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Columbia University, Herbert Irving Comprehensive Cancer Center	New York	New York	10032	—
Memorial Sloan Kettering Cancer Center	New York	New York	10065	—
Sidney Kimmel Cancer Center - Jefferson Health	Philadelphia	Pennsylvania	19107	—
Sarah Cannon Research Institute	Nashville	Tennessee	37205	—
MD Anderson Cancer Center	Houston	Texas	77030	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04879017, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 25, 2024 · Synced Nov 13, 2026